Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors

Table 2 Summary of common recurrently amplified regions^{a, b}

Cytogenetic region	Mb start position (BAC)	Mb end position (BAC)	Size (Mb)	Genes^c	No. cases
1p34	39.27 (RP11-528I12)	40.26 (RP11-747C18)	1.0	MACF1, PABPC4, TRIT1	3 (8%)
1q23	157.00 (RP11-735D24)	157.81 (RP11-812N5)	0.8	-	4 (11%)
2p25	9.42 (RP11-360P14)	10.34 (RP11-360P14)	0.9		3 (8%)
3p25	10.20 (RP13-635L13)	12.52 (RP11-738A2)	2.3	TATDN2, SEC13L1, VGLL4	3 (8%)
6p22	20.07 (RP11-345F7)	22.08 (RP11-630B10)	1.8		8 (21%)
8q22	101.23 (RP11-321E7)	102.99 (RP11-811I18)	1.8		5 (13%)
10q22	76.24 (RP11-368I19)	78.49 (RP11-272P2)	2.3	MYST4	3 (8%)
11q13	69.07 (CTD-2192B11)	70.20 (CTD-2011L13)	1.1	CCND1, ORAOV1, PPFIA1, CTTN	3 (8%)
16p13	10.59 (RP11-78D17)	12.84 (RP11-310B24)	2.3	NUBP1, DEXI, TXNDC11, ZC3H7A, RSL1D1, GSPT1	3 (8%)

^aMapping data is based on the UCSC genome browser (May 2004 freeze), and listed regions represent core amplicons.
^bOnly regions amplified in at least 3 cases are listed.
^cGenes that showed top ranking expression levels when genomically amplified. More detailed data for the 6p22, 8q22, and for 2p25 is given in Additional file 3.

ISSN: 1755-8794